JP2012518398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518398A5 JP2012518398A5 JP2011550601A JP2011550601A JP2012518398A5 JP 2012518398 A5 JP2012518398 A5 JP 2012518398A5 JP 2011550601 A JP2011550601 A JP 2011550601A JP 2011550601 A JP2011550601 A JP 2011550601A JP 2012518398 A5 JP2012518398 A5 JP 2012518398A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding
- binding construct
- domain
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 210000003127 knee Anatomy 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 claims 1
- 102000003930 C-Type Lectins Human genes 0.000 claims 1
- 108090000342 C-Type Lectins Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010059013 Chaperonin 10 Proteins 0.000 claims 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 102000000470 PDZ domains Human genes 0.000 claims 1
- 108050008994 PDZ domains Proteins 0.000 claims 1
- 108010079855 Peptide Aptamers Proteins 0.000 claims 1
- 208000018286 Shoulder injury Diseases 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000013069 gamma-Crystallins Human genes 0.000 claims 1
- 108010079934 gamma-Crystallins Proteins 0.000 claims 1
- 210000001624 hip Anatomy 0.000 claims 1
- 210000004394 hip joint Anatomy 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15488009P | 2009-02-24 | 2009-02-24 | |
| US61/154,880 | 2009-02-24 | ||
| PCT/EP2010/052283 WO2010097385A1 (en) | 2009-02-24 | 2010-02-23 | Antigen-binding constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012518398A JP2012518398A (ja) | 2012-08-16 |
| JP2012518398A5 true JP2012518398A5 (enExample) | 2013-04-11 |
Family
ID=42174088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550601A Pending JP2012518398A (ja) | 2009-02-24 | 2010-02-23 | 抗原結合性構築物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110305692A1 (enExample) |
| EP (1) | EP2401298A1 (enExample) |
| JP (1) | JP2012518398A (enExample) |
| CA (1) | CA2753287A1 (enExample) |
| WO (1) | WO2010097385A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| CA2763493A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Ltd. | Antigen-binding proteins |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| EP2632948B1 (en) | 2010-10-27 | 2016-11-16 | Spiber Technologies AB | Spider silk fusion protein structures for binding to an organic target |
| EP2683735A1 (en) * | 2011-03-10 | 2014-01-15 | HCO Antibody, Inc. | Bispecific three-chain antibody-like molecules |
| RU2661677C2 (ru) * | 2011-05-27 | 2018-07-18 | Аблинкс Нв | Ингибирование резорбции кости с помощью связывающих rank-l пептидов |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| MX2014001019A (es) * | 2011-07-27 | 2014-05-13 | Glaxo Group Ltd | Dominios variables singulares anti-vgf fusionados con dominios de fc. |
| HUE068728T2 (hu) | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JP6302895B2 (ja) | 2012-05-02 | 2018-03-28 | スパイバー テクノロジーズ アーベーＳｐｉｂｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ａｂ | 親和性リガンドとして免疫グロブリン断片を組み込んだクモ糸融合タンパク質の構造 |
| US9708376B2 (en) | 2012-05-02 | 2017-07-18 | Spiber Technologies Ab | Spider silk fusion protein structures without repetitive fragment for binding to an organic target |
| CN105051204B (zh) | 2012-11-16 | 2023-07-21 | 波赛伊达治疗学股份有限公司 | 位点特异性酶和使用方法 |
| US9353163B2 (en) * | 2013-03-14 | 2016-05-31 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| MA39061A1 (fr) | 2013-11-20 | 2017-10-31 | Regeneron Pharma | Modulateurs d'aplnr et leurs utilisations |
| RU2016141307A (ru) | 2014-03-21 | 2018-04-24 | Регенерон Фармасьютикалз, Инк. | Отличные от человека животные, которые вырабатывают однодоменные связывающие белки |
| EP3157328B1 (en) * | 2014-06-17 | 2021-08-04 | Poseida Therapeutics, Inc. | A method for directing proteins to specific loci in the genome and uses thereof |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| DK3310909T3 (da) | 2015-06-17 | 2021-09-13 | Poseida Therapeutics Inc | Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet |
| AU2023307708A1 (en) * | 2022-07-11 | 2024-11-28 | Amgen Inc. | Treatment of erosive hand osteoarthritis |
| FR3147278A1 (fr) * | 2023-03-31 | 2024-10-04 | Avacta Life Sciences Limited | Polypeptides de liaison au tnfr2 et procedes d'utilisation |
| FR3147292A1 (fr) * | 2023-03-31 | 2024-10-04 | Affyxell Therapeutics Co., Ltd. | Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations |
| WO2024200987A1 (en) * | 2023-03-31 | 2024-10-03 | Avacta Life Sciences Limited | Tnfr2 binding polypeptides and methods of use |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| DK1801214T3 (da) | 1997-07-07 | 2011-01-24 | Medical Res Council | In vitro sorteringsfremgangsmåde |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| ATE380865T1 (de) | 1998-05-13 | 2007-12-15 | Domantis Ltd | Phagen-display-selektionssystem für korrekt gefaltete proteine |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
| JP2003523742A (ja) | 2000-02-03 | 2003-08-12 | ドマンティス リミテッド | コンビナトリアルタンパク質ドメイン |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| ES2706902T3 (es) | 2001-06-26 | 2019-04-01 | Amgen Inc | Anticuerpos para OPGL |
| CA2457636C (en) | 2001-08-10 | 2012-01-03 | Aberdeen University | Antigen binding domains |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| TWI323734B (en) * | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| JP2009526857A (ja) | 2006-02-15 | 2009-07-23 | イムクローン・リミテッド・ライアビリティ・カンパニー | 機能性抗体 |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| CN101796072B (zh) * | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| KR20100018040A (ko) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
-
2010
- 2010-02-23 EP EP10711861A patent/EP2401298A1/en not_active Withdrawn
- 2010-02-23 JP JP2011550601A patent/JP2012518398A/ja active Pending
- 2010-02-23 CA CA2753287A patent/CA2753287A1/en not_active Abandoned
- 2010-02-23 WO PCT/EP2010/052283 patent/WO2010097385A1/en not_active Ceased
- 2010-02-23 US US13/202,996 patent/US20110305692A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518398A5 (enExample) | ||
| JP2016524592A5 (enExample) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2017163973A5 (enExample) | ||
| JP2019507589A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| WO2010115995A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders | |
| JP2013541335A5 (enExample) | ||
| HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| JP2019533807A5 (enExample) | ||
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2017029157A5 (enExample) | ||
| JP2016511254A5 (enExample) | ||
| JP2020501550A5 (enExample) | ||
| HRP20200679T1 (hr) | Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji | |
| JP2012518399A5 (enExample) | ||
| JP2018525032A5 (enExample) | ||
| RU2019121902A (ru) | Поливалентные модуляторы регуляторных t-клеток | |
| MX2009009194A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. | |
| RU2015146419A (ru) | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita |